Next generation immunotherapies sales will expand through 2036, with monoclonal antibodies holding 49.5% of the drug class segment in 2026. The market was valued at USD 130.45 billion in 2025 and is projected to grow from USD 139.8 billion in 2026 to USD 280.3 billion by 2036, creating an incremental opportunity of USD 140.43 billion.